<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Functional activation of oncogenic K-Ras signaling pathway plays an important role in the early events of colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>K-Ras proto-oncogene is involved in 35-40% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases </plain></SENT>
<SENT sid="2" pm="."><plain>Mutations in the Ras gene trigger the transduction of proliferative and anti-apoptotic signals, even in the absence of extra cellular stimuli </plain></SENT>
<SENT sid="3" pm="."><plain>The objective of the current study was to use a gene-targeting approach to kill human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells selectively harboring mutated K-Ras </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A recombinant adenovirus that carries a lethal gene, PUMA, under the control of a Ras responsive promoter (Ad-Py4-SV40-PUMA) was used selectively to target <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells (HCT116, SW480, DLD1 and RIE-Ras) that possess a <z:mp ids='MP_0001399'>hyperactive</z:mp> Ras pathway while using HT29 and RIE cells as a control that harbors <z:mp ids='MP_0002169'>wild type</z:mp> Ras and exhibit very low Ras activity </plain></SENT>
<SENT sid="5" pm="."><plain>Control vector, without the Ras responsive promoter elements was used to assess the specificity of our "gene therapy" approach </plain></SENT>
<SENT sid="6" pm="."><plain>Both adenoviral vectors were assed in vitro and in <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> in vivo </plain></SENT>
<SENT sid="7" pm="."><plain>Ad-Py4-SV40-PUMA showed high potency to induce ~50% <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in vitro, to abolish completely <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation by infecting cells with the Ad-Py4-SV40-PUMA prior xenografting them in <z:mp ids='MP_0003815'>nude</z:mp> mice and high ability to suppress by ~35% <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in vivo in already established <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Selective targeting of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells with the activated Ras pathway may be a novel and effective therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The high potency of this adenoviral vector may help to overcome an undetectable micro <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> that is the major hurdle in challenging with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>